Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $14.40.

A number of research analysts have commented on the stock. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 price target on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday, August 10th. BidaskClub cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Friday, August 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, September 14th.

Shares of Sangamo Therapeutics (NASDAQ SGMO) traded down 3.58% during mid-day trading on Friday, hitting $13.45. The stock had a trading volume of 2,249,390 shares. The firm has a 50 day moving average of $14.54 and a 200 day moving average of $9.48. The stock’s market cap is $1.12 billion. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $5.82 million. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The company’s revenue for the quarter was up 124.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.38) earnings per share. On average, analysts forecast that Sangamo Therapeutics will post ($0.82) earnings per share for the current year.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 11,474 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $10.44, for a total transaction of $119,788.56. Following the completion of the transaction, the vice president now owns 23,991 shares in the company, valued at $250,466.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $15.25, for a total transaction of $228,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,474 shares of company stock valued at $1,019,009. Corporate insiders own 5.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Cookson Peirce & Co. Inc. bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $317,000. RA Capital Management LLC bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $11,000,000. State Street Corp raised its stake in shares of Sangamo Therapeutics by 51.6% in the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after acquiring an additional 636,296 shares during the last quarter. DAFNA Capital Management LLC bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $1,980,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Sangamo Therapeutics by 53.5% in the second quarter. Goldman Sachs Group Inc. now owns 100,176 shares of the biopharmaceutical company’s stock valued at $881,000 after acquiring an additional 34,913 shares during the last quarter. Institutional investors own 63.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) Receives Average Recommendation of “Hold” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/22/sangamo-therapeutics-inc-sgmo-receives-average-recommendation-of-hold-from-analysts.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.